Genmab (NASDAQ:GMAB) has announced a significant surge in global net trade sales of its flagship oncology drug DARZALEX® (daratumumab), reaching a total of $2,878 million in the second quarter of 2024.
The sales figures, as reported by its licensing partner Johnson & Johnson, show a remarkable performance, with $1,641 million generated in the U.S. and $1,237 million from other global markets.
DARZALEX®, available in both intravenous and subcutaneous forms—the latter known as DARZALEX FASPRO® in the U.S.—continues to dominate its market segment.
Genmab receives royalties from worldwide net sales of both forms under an exclusive licensing agreement with Janssen, which handles the development, manufacturing, and commercialization of the drug.
Celebrating its 25th anniversary, Genmab remains committed to revolutionizing patient care through innovative antibody therapeutics.
The company boasts a rich pipeline of advanced drug candidates, including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators, and effector function-enhanced antibodies.
By 2030, Genmab aims to transform the lives of individuals suffering from cancer and other serious diseases with its knock-your-socks-off (KYSO®) antibody medicines.